B+L INTRODUCES VITAMIN TO FILTER BLUE LIGHT
Bausch + Lomb has introduced Ocuvite Blue Light eye vitamins, a nutritional supplement formulated to protect eyes from blue light that comes with increased usage of digital devices. Ocuvite Blue Light eye vitamins contain 25mg of lutein and 5mg of zeaxanthin isomers, the key eye nutrients that help absorb blue light before it reaches the macula. Ocuvite Blue Light eye vitamins will be available for purchase in the vitamin and eyecare aisles at major retailers in the third quarter of 2018.
B+L also introduced Soothe Xtra Protection (XP) Preservative Free lubricant eyedrops, which combine Restoryl mineral oils to restore the lipid layer, seal in moisture, and protect against further irritation. For information, go to Ocuvite.com and SootheEyedrops.com.
LACRYDIAG ANALYZES TEAR FILM OF INDIVIDUALS WITH DRY EYE
Quantel Medical, a subsidiary of the LUMIBIRD Group, has launched LacryDiag, an ocular surface analyzer that lets you determine the cause of a patient’s dry eye in order to offer the appropriate treatments. Specifically, LacryDiag offers four non-contact exams: interferometry to evaluate the lipid layer, noninvasive tear breakup time (NIBUT) to evaluate the mucin layer, tear meniscus to evaluate the aqueous layer, and meibography to evaluate the meibomian glands. For information, go to Quantel-Medical.com.
OPTOVUE’S ANGIOANALYTICS APPROVED FOR BLOOD VESSEL MEASUREMENT
Optovue has received FDA 510(k) clearance of AngioAnalytics, which works with its AngioVue optical coherence tomography angiography (OCTA) to provide high-resolution imaging of retinal blood vessels. The two technologies create color-encoded maps of the vessel densities of the retina or optic nerve and provide analyses of areas in which there is blood vessel loss (nonperfusion), abnormal blood vessel growth (flow area), and several parameters to assess change to the foveal avascular zone, an area of the retina profoundly affected by diabetic retinopathy. The new AngioAnalytics software also provides trend analysis so that physicians can objectively monitor retinal and vascular changes caused by disease progression or from treatment.
Optovue also received clearance for its 3D projection artifact removal (3D PAR) software, which is designed to improve OCTA image quality and enable accurate measurement and interpretation of OCTA images. Projection artifacts occur when ghost images of blood vessels that exist in one retinal layer are projected onto other layers.
In other news, Optovue, has received expanded FDA 510(k) clearance for its epithelial thickness mapping software, which is now available on the Avanti Widefield OCT system. The expanded clearance adds a 9mm ETM scan to the previously available 6mm one to detect epithelial irregularities. For information, go to Optovue.com.